AMAG Pharmaceuticals (AMAG Pharmaceuticals) Total Liabilities : $478.3 Mil (As of Sep. 2020)

View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Total Liabilities?

AMAG Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2020 was $478.3 Mil.

AMAG Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2020 ($489.84 Mil) to Jun. 2020 ($466.23 Mil) but then increased from Jun. 2020 ($466.23 Mil) to Sep. 2020 ($478.33 Mil).

AMAG Pharmaceuticals's annual Total Liabilities declined from Dec. 2017 ($1,110.11 Mil) to Dec. 2018 ($433.90 Mil) but then increased from Dec. 2018 ($433.90 Mil) to Dec. 2019 ($511.41 Mil).

AMAG Pharmaceuticals Total Liabilities Historical Data

The historical data trend for AMAG Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Total Liabilities Chart

AMAG Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Liabilities

Get a 7-Day Free Trial

1,543.95

1,544.04

1,110.11

433.90

511.41

AMAG Pharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Total Liabilities	Get a 7-Day Free Trial															485.98	511.41	489.84	466.23	478.33

AMAG Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AMAG Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2019 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	214.497	+	(296.825	+	0.088999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	511.4

Total Liabilities	=	Total Assets (A: Dec. 2019 )	-	Total Equity (A: Dec. 2019 )
	=	791.227	-	279.816
	=	511.4

AMAG Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	161.977	+	(308.06	+	0.63499999999997
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	7.662	+	0)
	=	478.3

Total Liabilities	=	Total Assets (Q: Sep. 2020 )	-	Total Equity (Q: Sep. 2020 )
	=	734.356	-	256.022
	=	478.3

AMAG Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.amagpharma.com

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Executives

Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano	officer: Chief Operating Officer	C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos	officer: Interim CFO	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson	director, 10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat	director
Davey Scoon	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers	director, officer: President & CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick	officer: Chief Human Resources Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022